Stada Arzneimittel partners with Gedeon Richter to distribute biosimilar Pegfilgrastim in Europe

10 August 2015

Germany-based Stada Arzneimittel (SAZ: Xetra) said it has partnered with Hungary's largest drugmaker Gedeon Richter (RICHT: HB) to distribute the latter’s biosimilar Pegfilgrastim in Europe.

Under the terms of the deal Stada will receive non-exclusive distribution rights in Europe (excluding Russia), while Richter will retains its rights to distribute and market the biosimilar of Amgen's (Nasdaq: AMGN) Neulasta for rest of the world.

Hartmut Retzlaff, chairman of Stada Arzneimittel, said: “With the agreement, we ensure that we will be able to offer a low-cost and high-quality alternative to the original product immediately following the expiration of the patent in 2017. This way, we also further expand our position in the promising and attractive-margin biosimilar market and strengthen our portfolio with an additional biosimilar in a low cost and low risk manner.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK